Tango Therapeutics
Develops MTAP-selective PRMT5 inhibitors for genetically defined cancers.
Something off on this page? Send us feedback.
Profile
Develops biomarker-selected cancer drugs built around synthetic lethality, led by vopimetostat combinations for MTAP-deleted pancreatic and lung cancers and brain-penetrant TNG456 for glioblastoma. Has no approved products or product sales; progress depends on clinical results, regulatory clearance, collaborators, and outsourced manufacturing.
Develops precision-oncology drugs for genetically defined cancers by pairing synthetic-lethality target discovery with biomarker-selected clinical trials. The lead program, vopimetostat, is an MTAP-selective PRMT5 inhibitor in clinical development alone and with RAS-targeted therapies for pancreatic and lung cancers; the daraxonrasib combination is moving toward late-stage planning.
A second PRMT5 candidate, TNG456, is designed to reach the brain and is being tested in MTAP-deleted glioblastoma and other solid tumors. The broader pipeline includes TNG260, a CoREST inhibitor for a genetically defined lung-cancer subgroup, and the preclinical HBS1L degrader TNG961.
Operates as a clinical-stage biotechnology business without approved products or product sales. Progress depends on trial outcomes, regulatory approval, collaboration partners including Revolution Medicines and Erasca, and third-party clinical and manufacturing providers.
Company facts
Key statistics
Year to date +162% · Average volume (30d) 2.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | H.C. Wainwright | Reiterate | Buy | $66 | $68 | |
| Aug 12, 2026 | Guggenheim | Reiterate | Buy | $12 | $35 | |
| Jul 17, 2026 | Mizuho Securities | Target | $36 | $40 | ||
| Jun 29, 2026 | Canaccord Genuity | Reiterate | Buy | $42 | $46 | |
| Jun 26, 2026 | Jefferies | Upgrade | Hold | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.32 | −$0.37 | −16.6% | $1.6M | $0 | −100.0% | −4.81% |
| Aug 10, 2026Q2 FY26 | −$0.32 | −$0.37 | −16.6% | $1.6M | — | — | +2.22% |
| May 13, 2026Q1 FY26 | −$0.32 | −$0.32 | 0.0% | $578.1K | — | — | −2.51% |
| Mar 5, 2026Q4 FY25 | −$0.31 | −$0.29 | +6.5% | $500.4K | — | — | +0.71% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $3.2M | $53.8M | $0 | $0 | $0 | |
| Gross profit | $5.4M | $2.6M | $53.8M | −$479.0K | −$463.0K | $0 | |
| Operating income | −$42.5M | −$41.0M | $14.1M | −$41.9M | −$48.8M | −$59.8M | |
| Net income | −$39.9M | −$38.9M | $15.9M | −$38.7M | −$45.5M | −$55.3M | |
| Diluted EPS | −$0.36 | −$0.35 | $0.14 | −$0.30 | −$0.32 | −$0.37 | |
| Gross margin | 100.0% | 80.4% | 100.0% | — | — | — | |
| Operating margin | -788.8% | -1,287.9% | 26.2% | — | — | — |
Fiscal years (4-quarter sums)FY21 $37.0M · FY22 $24.9M · FY23 $36.5M · FY24 $42.1M · FY25 $62.4M
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $1.01B · Total debt $32.0M · Total assets $1.07B · Shareholders' equity $1.02B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 162.81M · Float 106.26M · 65.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 13.90M | 8.54% | 13F | Aug 14, 2026 |
| Third Rock Ventures IV, L.P. · 10 percent owner | 13.39M | 8.22% | Form 4 | Oct 27, 2025 |
| BlackRock, Inc. | 12.44M | 7.64% | 13F | Aug 7, 2026 |
| FMR LLC | 12.33M | 7.58% | 13F | Aug 13, 2026 |
| Farallon Capital Management LLC | 12.28M | 7.54% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $27.24 |
| Jul 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $29.59 |
| Jun 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $22.87 |
| May 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $21.23 |
| Apr 15, 2026 | Adam Crystal | officer: President, R&D | −38,460 | $25.00 |
Peers
- Bristol-Myers Squibb
Most direct PRMT5-MTA benchmark in MTAP-deleted solid tumors
- Amgen
Clinical PRMT5 peer with AMG 193 in MTAP-deleted tumors
- IDEAYA Biosciences
MTAP pathway peer spanning MAT2A and PRMT5 programs
- AstraZeneca (ADR)
Big-pharma PRMT5 entrant with AZD3470 in MTAP-deficient tumors
- BeOne Medicines (ADR)
PRMT5 and MAT2A oncology peer in MTAP-deficient tumors
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tango Therapeutics | $23.49 | +0.56% | $3.80B | — | — | 70.6 | −100.0% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| IDEAYA Biosciences | $40.11 | −0.05% | $3.81B | — | — | 16.3 | — |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| BeOne Medicines (ADR) | $366.73 | −0.01% | $39.19B | 5.1 | 46.7 | 6.9 | +29.6% |
| Median | 19.5 | 16.8 | 6.1 | +8.0% |